Cambridge Research Biochemicals (CRB) will continue to supply The Medical Research Council (MRC) with custom-synthesised peptides and bespoke polyclonal and monoclonal antibodies for a further 12 months as a valued preferred supplier under a new pricing agreement.
Having delighted customers with the highest quality products during its 35 years of service in the life science industry, CRB, who are based in the North East of England in Billingham on Teesside, has announced a fixed pricing agreement with UK SBS, formerly known as RCUK Shared Services Centre Ltd (RCUK SSC Ltd). With the original contract being issued in 2010, this will be the fifth year that CRB have maintained preferred supplier status.
CRB have also extended their pricing, which has now been frozen since 2013, to the Francis Crick Institute, which includes the former MRC site The National Institute for Medical Research (NIMR) based in Mill Hill, North London. The agreed pricing will also be carried forward once The Crick Institute site located at Kings Cross St Pancreas is fully established. In the meantime, all Crick subsidiaries are also invited to enjoy the discount opportunities.
Establishment of this new pricing agreement is extremely significant to CRB as it not only consolidates the existing relationships with the Medical Research Council (MRC), but also allows the company to continue to enhance and progress relations with new MRC Institutes, in addition to exploring avenues into other UK based Universities.
Cambridge Research Biochemicals (CRB) Commercial Director Emily Humphrys said: “This announcement certifies CRB’s strong position as a key player in the busy global peptide and antibody market and portrays the consistently high level of quality life-science products that are supplied to the Medical Research Council.”” “CRB celebrates its 35th Anniversary of service this July and is delighted to continue to supply the Medical Research Council and other affiliated institutes with superior custom research tools. Since CRB’ s expansion and relocation in January 2014, the peptide and antibody portfolio offered to the MRC has expanded further still, with increased capacity which now also includes monoclonal antibody generation in a brand new cell culture suite. “The contract renewal also signifies the trust and confidence that the Medical Research Council have placed in CRB.”
Mike Reilly, Category Manager for UK SBS Ltd, said: “The continuation of CRB’s preferred supplier status under the new pricing agreement demonstrates the faith that UKSBS have in the admirable work being done by the team at CRB. During the time that we have worked together, CRB have displayed an exemplary commitment to the quality and ethical standards of the products that they supply to us. We look forward further developing our relationship over many years to come.